ETNB (89bio Pharma) Earnings growth in current year

ETNB (89bio Pharma) - company brandmark

The development of 89bio, Inc. (ETNB) relies on the success of final trials for its liver dysfunction drug. The strategy focuses on creating the blockbuster pegozafermin to capture the MASH market. The annual earnings per share change visualizes capital dynamics, where 36.70 represents the latest level. High authority within the scientific community positions the company as a promising leader in the fight against the NASH epidemic.

ETNB: 89bio, Inc. Earnings per share growth in current year 07/04/2022 - 11/15/2025

Financial and market metric breakdowns for 89bio Inc (ETNB)

- share price and expert price forecast:
Price 89bio Corp|ETNB - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization 89bio|ETNB - Enterprise Value
- book capitalization data:
Net Assets per Single Share 89bio|ETNB - Company Book Value|Market-to-Book Ratio 89bio.com|ETNB - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Equity 89bio, Inc.|ETNB - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient 89bio Inc|ETNB - Company Debts|Debts to Net Assets 89bio, Inc.|ETNB - Company Long-Term Debt|Company Current Liabilities 89bio|Interim Coverage Ratio 89bio.com
- earnings and valuation multiples information:
ETNB - Net Profit|Expected Profit 89bio, Inc.|ETNB - P/E Multiple|Market Cap to Projected Earnings 89bio.com|ETNB - Price/Earnings to Growth Ratio|Company Value to EBITDA 89bio Inc|ETNB - Operating profit before deduction of amortization|Earnings per share for the trailing year 89bio|ETNB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months 89bio.com|ETNB - Earnings per share growth in current year|Projected earnings per share growth rate for next year 89bio, Inc.
- revenue and sales proceeds data:
ETNB - Revenue and Sales Volume|Company Future Sales Volume 89bio, Inc.|ETNB - Market Cap to Revenue|Market Cap to Expected Sales Ratio 89bio
Basic company analysis:ETNB - 89bio Pharma
Finished products of 89bio

For the biotechnology sector company 89bio, Inc. (ETNB), earnings per share dynamics serve as an indicator of cost management efficiency amid the systematic execution of clinical trials and capacity preparation. By analyzing the annual change in earnings per share, an investor assesses the percentage deviation of the current EPS from the previous year, which allows for the identification of the impact of currency risks and operational overhead on the issuer's final dollar value.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year Agios Corp|Structure Corp (GPCR) - Expected net earnings per share growth this year|Earnings per share growth in current year mimedx.com (MDXG)|Net earnings per share growth this year rezolutebio.com RZLT|Earnings per share growth in current year Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Earnings per share growth in current year|ALT: Net earnings per share growth this year|AARD - Earnings growth in current year|SGMT: Earnings growth in current year|Earnings per share growth rate in current year BioAge Labs, Inc. (BIOA)|Earnings per share growth in current year Biomea Fusion Inc|Earnings per share growth this year QNCX (Quince Therapeutics)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year